S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:NRBO

NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

$6.24
+0.45 (+7.77%)
(As of 03/1/2024 ET)
Today's Range
$5.52
$6.34
50-Day Range
$3.02
$6.24
52-Week Range
$2.89
$7.60
Volume
409,595 shs
Average Volume
624,864 shs
Market Capitalization
$30.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NeuroBo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of NeuroBo Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.20) to ($3.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.33 out of 5 stars

Medical Sector

916th out of 950 stocks

Pharmaceutical Preparations Industry

425th out of 440 stocks


NRBO stock logo

About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NRBO Stock Price History

NRBO Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
NeuroBo Pharma'a IND Application For DA-1726 Gets FDA Clearance
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Neurobo Pharmaceuticals Inc (NRBO)
See More Headlines
Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/03/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRBO
Employees
2
Year Founded
N/A

Profitability

Net Income
$-13,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.84 per share

Miscellaneous

Free Float
4,814,000
Market Cap
$30.26 million
Optionable
Not Optionable
Beta
-0.24
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Hyung-Heon Kim (Age 49)
    CEO, President, Principal Executive & Director
    Comp: $54.22k
  • Mr. Marshall H. Woodworth (Age 66)
    Acting CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Mi-Kyung Kim
    Chief Scientific Officer
  • Mr. Robert Homolka
    Senior Vice President of Clinical Operations














NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed in 2024?

NeuroBo Pharmaceuticals' stock was trading at $3.70 at the beginning of the year. Since then, NRBO stock has increased by 68.6% and is now trading at $6.24.
View the best growth stocks for 2024 here
.

Are investors shorting NeuroBo Pharmaceuticals?

NeuroBo Pharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 131,700 shares, an increase of 395.1% from the January 31st total of 26,600 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is presently 0.1 days. Approximately 4.1% of the company's stock are sold short.
View NeuroBo Pharmaceuticals' Short Interest
.

When is NeuroBo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our NRBO earnings forecast
.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings data on Monday, November, 15th. The company reported ($38.40) EPS for the quarter, topping analysts' consensus estimates of ($43.20) by $4.80.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals shares reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).

Who are NeuroBo Pharmaceuticals' major shareholders?

NeuroBo Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRBO) was last updated on 3/3/2024 by MarketBeat.com Staff